drugset / Trial / NCT02592421

SGLT2 Inhibition and Stimulation of Endogenous Glucose Production: Protocol 2

NCT02592421

RandomizedParallel-groupSingle-blindTreatment

Summary

In Protocol 2, the investigators will determine the role of pancreatic hormones (increase in plasma glucagon and decrease in plasma insulin concentration) in the stimulation of EGP following SGLT2 inhibition.

Timeline

Start
2015-10-23
Primary completion
2018-10-01
Completion
2019-10-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator Dapagliflozin Small molecule 10 mg